Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Bonetti

Showing results (41-50 of 132) with videos related to

Pageof 14
Sort By:
International Journal of Colorectal Disease|September 10, 2018
First-line therapies in metastatic colorectal cancer: integrating clinical benefit with the costs of drugsJacopo Giuliani, Andrea Bonetti
Clinical Lung Cancer|May 16, 2017
Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic CostsJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|August 30, 2016
The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients treated with targeted agentsJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|June 15, 2021
Alectinib in first-line treatment for advanced anaplastic lymphoma kinase mutation-positive (alk+) non-small cell lung cancer (NSCLC): a cost-effective changeJacopo Giuliani, Andrea Bonetti
Clinical Colorectal Cancer|May 20, 2020
Economic Sustainability of Trifluridine/Tipiracil for the Treatment of Refractory Metastatic Colorectal Cancer in Real LifeJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|June 21, 2017
Jacopo Giuliani, Andrea Bonetti
Clinical Lung Cancer|January 19, 2016
Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled TrialsJacopo Giuliani, Andrea Bonetti
Journal of Medical Virology|November 20, 2020
COVID-19 and cancer: A clear change not only in daily clinical practice but also in clinical research managementJacopo Giuliani, Andrea Bonetti
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (<i>EGFR</i>)-mutations in first-line for advanced non-small cell lung cancerJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|January 19, 2016
[Platinum antitumor complexes]Andrea Bonetti, Jacopo Giuliani, Franco Muggia
Pageof 14

Showing results (41-50 of 132) with videos related to

Sort By:
Pageof 14
International Journal of Colorectal Disease|September 10, 2018
First-line therapies in metastatic colorectal cancer: integrating clinical benefit with the costs of drugsJacopo Giuliani, Andrea Bonetti
Clinical Lung Cancer|May 16, 2017
Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic CostsJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|August 30, 2016
The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients treated with targeted agentsJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|June 15, 2021
Alectinib in first-line treatment for advanced anaplastic lymphoma kinase mutation-positive (alk+) non-small cell lung cancer (NSCLC): a cost-effective changeJacopo Giuliani, Andrea Bonetti
Clinical Colorectal Cancer|May 20, 2020
Economic Sustainability of Trifluridine/Tipiracil for the Treatment of Refractory Metastatic Colorectal Cancer in Real LifeJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|June 21, 2017
Jacopo Giuliani, Andrea Bonetti
Clinical Lung Cancer|January 19, 2016
Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled TrialsJacopo Giuliani, Andrea Bonetti
Journal of Medical Virology|November 20, 2020
COVID-19 and cancer: A clear change not only in daily clinical practice but also in clinical research managementJacopo Giuliani, Andrea Bonetti
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (<i>EGFR</i>)-mutations in first-line for advanced non-small cell lung cancerJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|January 19, 2016
[Platinum antitumor complexes]Andrea Bonetti, Jacopo Giuliani, Franco Muggia
Pageof 14